First disclosure of results from primary analysis of Phase 2 PILOT study shows Breyanzi delivered complete responses in more than half of patients with refractory or relapsed large B-cell lymphoma after first-line therapy who were not deemed candidates for stem cell transplant PILOT patient-reported outcomes analysis showed treatment with Breyanzi improved health-related quality of life … [Read more…]

SAN DIEGO & TOKYO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 … [Read more…]

Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line combination study in patients with recurrent or metastatic cervical cancer Several abstracts evaluating Genmab owned and partnered programs accepted for presentation COPENHAGEN–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several … [Read more…]

– Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma – – Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma – … [Read more…]

The new clinic specializes in treating workplace injuries for Tucson’s business community TUCSON, Ariz.–(BUSINESS WIRE)–On Site Medical (OSM)—an Arizona-based provider of industrial medicine solutions—today announced the opening of its new Tucson urgent care clinic, centrally located at 5th and Alvernon (630 N. Alvernon Way, Suite 260). Like all of OSM’s offerings, the clinic will specialize … [Read more…]

Nearly half of parents report their children have experienced increased anxiety or have lost friendships; sleep and eating disorders more than double NEW YORK–(BUSINESS WIRE)–A national survey of parents conducted by Elemy (https://www.elemy.com/) the nationwide provider of childhood behavioral and mental healthcare, revealed deeply concerning impacts the COVID-19 pandemic has had on childhood mental health. … [Read more…]

AMSTERDAM–(BUSINESS WIRE)–VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces presentation of a poster at the European Network to Cure ALS (ENCALS) Annual Meeting at the University of Edinburgh on 1-3 June, 2022. Members of the VectorY … [Read more…]

CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA–(BUSINESS WIRE)–Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of … [Read more…]

Special Celebration at Azusa Pacific University on June 4 to Feature Star-Studded Talent Lineup, Led by ABC7 News Anchor Phillip Palmer LOS ANGELES–(BUSINESS WIRE)–#2022DonateLifeRunWalk–Celebrating 20 years of inspiring local communities to donate life, OneLegacy’s 2022 Donate Life Run/Walk will host an in-person event on June 4 at Azusa Pacific University’s soccer fields. With a new … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “North America Clinical Trials Market 2021-2031 by Product Category, Phase, Design, Service Type, Indication, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. North America clinical trials market is projected to grow by 6.9% annually in the forecast period and reach $39,268.7 million by 2031, driven … [Read more…]